When patients cannot take pills: Antiretroviral drug formulations for managing adult HIV infection

Topics in Antiviral Medicine

Volumn 19, Issue 3, 2011, Pages 126-131

  Nyberg, Chessa R ^a   Patterson, Brooke Y ^b   Williams, Meghan M ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c Advanced Response Management Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; BIOAVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; REVIEW;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL AVAILABILITY; HIV INFECTIONS; HUMANS;

EID: 84878876651     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2005. Vol 17. Revised June 2007. http://www.cdc.gov/hiv/topics/surveil lance/resources/reports/2005report/ pdf/2005SurveillanceReport.pdf. Accessed August 12, 2011.
2. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
4. Law M, Friis-Møller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4: 1-10.
5. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://aidsinfo. nih.gov/contentfiles/AdultandAdolescent GL.pdf. Accessed June 22, 2011.
7. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. http://www.aids info.nih.gov/ContentFiles/AdultandAdo lescentGL.pdf. Accessed June 16, 2011.
9. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43 (Suppl 9):III40-III52.
10. Heelon M, Skiest D, Tereso G, et al. Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients. Am J Health Syst Pharm. 2007;64:2064-2068.
11. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook. 18th ed. Hudson, OH: Lexi-Comp, Inc.; 2009.
12. Clinical Pharmacology. Tampa, FL: Elsevier/Gold Standard; 2006. http:// www.clinicalpharmacology.com. Accessed August 12, 2011.
13. Facts & Comparisons. St. Louis, MO: Wolters Kluwer Health; 2010. http://www. factsandcomparisons.com. Accessed June 22, 2011.
14. Stone VE, Mansourati FF, Poses RM, Mayer KH. Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. J Gen Intern Med. 2001;16:360-368.
15. Rastegar DA, Knight AM, Monolakis JS. Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis. 2006;43:933-938.
16. Kiertiburanakul S, Sungkanuparph S. Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention. Curr HIV Res. 2009;7:273-278.
17. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380.
18. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
19. Delavirdine [package insert]. New York, NY: Pfizer Inc; 2008.
20. Efavirenz [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2010.
21. Etravirine [package insert]. Titusville, NJ: Tibotec Therapeutics; 2010.
22. Nevirapine [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2010.
23. Rilpivirine [package insert]. Titusville, NJ: Tibotec Pharmaceuticals; 2011.
24. Abacavir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
25. Didanosine [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2010.
26. Emtricitabine [package insert]. Foster City, CA: Gilead Sciences, Inc; 2008.
27. Lamivudine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
28. Stavudine [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009.
29. Zidovudine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
30. Atazanavir [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2010.
31. Darunavir [package insert]. Titusville, NJ: Tibotec Therapeutics; 2010.
32. Fosamprenavir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
33. Indinavir [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2010.
34. Lopinavir/ritonavir [package insert]. Abbott Park, IL: Abbott Laboratories; 2010.
35. Nelfinavir [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc; 2010.
36. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009; 1-139. http:// aidsinfo.nih.gov/ContentFiles/Pediatric Guidelines.pdf. Accessed June 22, 2011.
37. Ritonavir [package insert]. Abbott Park, IL: Abbott Laboratories; 2010.
38. Saquinavir [package insert]. South San Francisco, CA: Genentech, Inc; 2010.
39. Tipranavir [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2010.
40. Raltegravir [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2010.
41. Fixed-dose combination efavirenz/emtricitabine/tenofovir [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2010.
42. Fixed-dose combination rilpivirine/emtricitabine/tenofovir [package insert]. Foster City, CA: Gilead Sciences, Inc; 2011.
43. Fixed-dose combination abacavir/lamivudine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
44. Fixed dose combination abacavir/lamivudine/zidovudine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
45. Fixed-dose combination emtricitabine/tenofovir [package insert]. Foster City, CA: Gilead Sciences; 2009.
46. Fixed-dose combination lamivudine/zidovudine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
47. Tenofovir [package insert]. Foster City, CA: Gilead Sciences, Inc; 2010.
48. Maraviroc [package insert]. New York, NY: Pfizer Inc; 2009.
49. Enfuvirtide [package insert]. South San Francisco, CA: Roche Laboratories; 2011.